Search
Larimar Therapeutics Inc
LRMRAdd to Watchlist
3.320USD
-0.545-14.10%
Close 09-24 16:00（ET）
344.88MMarket Cap
LossP/E TTM
Larimar Therapeutics Inc (LRMR) Stock Price Target & Forecast
Analyst Rating
Based on 11 analysts giving stock ratings to Larimar Therapeutics Inc in the past month.
Strong Buy
6 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
14.625USD+278.40%
LRMR Analyst Recommendation Trends
In the current month, LRMR has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LRMR average Analyst price target in the last month is 14.625.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
6
6
7
7
7
7
7
7
5
5
4
4
4
4
4
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
11
11
11
11
11
12
LRMR Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, LRMR EPS is projected to reach -0.344 in FY2026Q3, following reported EPS of -0.316 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.51
-0.54
-0.38
-0.34
-0.38
Actual
-0.73
-0.33
-0.32
--
--
Surprise
-44.49%
+38.37%
+17.21%
--
--
FAQs
What is Larimar Therapeutics Inc's price target?
Analysts forecast that Larimar Therapeutics Inc's price target is USD 14.62, with the highest forecast at USD 26.00 and the lowest forecast at USD 5.00.
How have Larimar Therapeutics IncLRMR's recent earnings per share performed?
The market expectation was USD -0.32, while Larimar Therapeutics IncLRMR's earnings per share (EPS) for the previous quarter was USD -0.33. EPS for the next quarter is expected at USD -0.34.
What is the analyst rating for Larimar Therapeutics Inc?
Based on the ratings of Larimar Therapeutics Inc's stock from 11 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.